MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

Autor: Cohen, Jonathon B. 1, Shah, Nirav N. 2, Alencar, Alvaro J. 3, Gerson, James N. 4, Patel, Manish R. 5, Fakhri, Bita 6, Jurczak, Wojciech 7, Tan, Xuan Ni 8, Lewis, Katharine L. 8, Fenske, Timothy 2, Coombs, Catherine C. 9, Flinn, Ian W. 10, Lewis, David J. 11, Gouill, Steven Le 12, Palomba, M. Lia 13, Woyach, Jennifer A. 14, Pagel, John M. 15, 16, Lamanna, Nicole 17, Barve, Minal A. 18, Ghia, Paolo 19, Eyre, Toby A. 20, Zinzani, Pier Luigi 21, Ujjani, Chaitra S. 22, Koh, Youngil 23, Izutsu, Koji 24, Lech-Maranda, Ewa 25, Tam, Constantine S. 26, Sundaram, Suchitra 27, Yin, Ming 16, Nair, Binoj 16, Tsai, Donald E. 16, Balbas, Minna 16, Mato, Anthony R. 13, Cheah, Chan Y. 8, Wang, Michael L. 28
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S394-S395
Databáze: ScienceDirect
Externí odkaz: